Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CTSG | P08311 | 5/20 | 0.42 |
| ▸ | KLK7 | P49862 | 5/20 | 0.42 |
| ▸ | KLK14 | Q9P0G3 | 5/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.42 |
| ▸ | CTRC | Q99895 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297264 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL17554019 | 0.71 | KLK7 (0.72) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL22952908 | 0.71 | KLK7 (0.67) | ALDH1A1KMT2AHPGDMAPTHSD17B10 | |
| SCHEMBL8499615 | 0.70 | KMT2A (0.70) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL914308 | 0.69 | KMT2A (0.65) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL915062 | 0.69 | KMT2A (0.64) | ALDH1A1KMT2AHPGDMAPTHSD17B10 | |
| SCHEMBL5772611 | 0.68 | ALDH1A1 (1.00) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL3453695 | 0.68 | NPC1 (0.65) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL692832 | 0.68 | ELANE (0.64) | ALDH1A1KMT2AHPGDF2MAPT | |
| SCHEMBL12927380 | 0.67 | RAB9A (0.58) | ALDH1A1KMT2AHPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198891-B2 | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase | NEW YORK UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | NEW YORK UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | ERN1, ERN2, EEF2K | ALDH1A1 4002/4885KMT2A 3197/4885HPGD 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.